Biotech’s Big Gamble Fails: Insights and Implications by Lilu Anderson 18.06.2024 Catch up on biotech headlines: Zentalis faces FDA hold, Aerovate's major setback, Merck's new vaccine, and promising trials by Intra-Cellular ...
Biotech’s Big Gamble Fails: Insights and Implications by Lilu Anderson 18.06.2024 Catch up on biotech headlines: Zentalis faces FDA hold, Aerovate's major setback, Merck's new vaccine, and promising trials by Intra-Cellular ...
7 Breakthrough Biotech Stocks to Boost Your Portfolio in 2023 by Lilu Anderson 18.06.2024 "Discover 7 breakthrough biotech stocks poised to boost your portfolio in a sector projected to reach $521.6B by 2033. Learn ...
Walmart, Home Depot Lead Annual Dividend Increases by Terry Bingman 20.02.2024 This article provides predictions for annual dividend increases for several long-term dividend growth companies, including Coca-Cola and UPS.
Tomorrow’s Top Stock Picks: Who Will Soar and Sink? by Mark Eisenberg 19.02.2024 Investors are advised on tomorrow's top stock picks as NVIDIA and Lam Research thrive, while Intel and Gilead Sciences face ...
Wall Street Gains: Fed and Data Insights by Terry Bingman 12.02.2024 U.S. stocks inch up as Wall Street reflects on a historic week, with the S&P 500 and Nasdaq Composite reaching ...
Gilead’s $4.3B Bet on CymaBay’s Liver Drug by Mark Eisenberg 12.02.2024 Gilead Sciences plans to acquire CymaBay Therapeutics for $4.3 billion, expanding their liver disease portfolio. The deal is expected to ...
Gilead Acquires CymaBay: Liver Cure Leap? by Mark Eisenberg 12.02.2024 Gilead Sciences acquires CymaBay Therapeutics for $4.3 billion to expand its liver disease portfolio, including access to potential treatment for ...
Oppenheimer Trims Gilead Sciences Price Target by Mark Eisenberg 12.02.2024 Oppenheimer lowers price target on Gilead Sciences after Q4 earnings report and challenges in drug pipeline. Optimistic about prospects for ...
Tomorrow’s Top Stock Picks: Winners & Losers Revealed by Mark Eisenberg 12.02.2024 Discover the winners and losers in the stock market, including tech giants Microsoft and NVIDIA, as well as underperformers Intel ...